HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kuhns, S. T. Articles by Pease, L. R. Search for Related Content PubMed PubMed Citation Articles by Kuhns, S. T. Articles by Pease, L. R.

A Region of Conformational Variability Outside the Peptide-Binding Site of a Class I MHC Molecule

Department of Biochemistry and Molecular Biology, Mayo Clinic/Foundation, Rochester, MN 55905

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
Peptide binding is known to influence the conformation of the surface of class I molecules as detected with mAbs and TCR. A new conformationally sensitive epitope on the mouse class I molecule K^b is defined by mAb AF6-88.5. The recognized structure is affected by amino acid substitutions in any of the three external domains of the class I heavy chain and, in addition, is influenced by the substitution of human for mouse ß₂-microglobulin. Interestingly, the epitope for this Ab is not affected by mutations within the peptide-binding cleft or by the nature of the peptide bound. These findings indicate that the effect of a change in one domain of class I can radiate to other parts of the molecule. Furthermore, the existence of conformationally sensitive structures outside of the peptide-binding site suggests the possibility that class I molecules may change their structure in response to binding by receptors and ligands such as the TCR and the coligand CD8. Such structural changes may represent signals that can influence cellular activation events.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
The elucidation of the static structures of several class I molecules, as well as two complexed with the TCR, have provided understanding of the molecular nature of immune recognition (1, 2, 3, 4). There remains the issue of how the conformation of the players in these interactions might undergo structural change during the formation of different complexes. While there have been numerous studies designed to look at the extent to which bound peptide or mutations in the 1 and 2 domains affect the overall conformation of the Ag-presentation domain of the complex, it is still unclear whether such changes may have structural consequences in the other regions of the molecule, or, conversely, the effect that conformational changes in 3 or ß₂-microglobulin (ß₂m)² have on the conformation of the Ag-presentation domain. A recent report describing the crystal structure of the complex between human CD8 and HLA-A2 finds that the position of the 3 domain is different from that in uncomplexed HLA-A2 (5). Taken together with the finding by Garcia et al. that the presence of CD8 enhances the formation of stable TCR/MHC complexes (6), these observations suggest that these shifts might occur to accommodate a higher-affinity interaction.

The present study describes features of the mouse class I molecule, K^b, which are important for the formation of the conformationally sensitive epitope of the mAb, AF6-88.5, produced by Loken and Stall (7). We find that even relatively subtle changes in any of the extracellular domains of the class I molecule, excluding the peptide-binding site, have an effect on the epitope recognized by AF6-88.5. This indicates that conformational perturbations that originate in one domain can radiate to affect the three dimensional structure of the other domains of the complex. Conformational plasticity provides a mechanism for transmitting signals along the class I molecule as a consequence of being bound by its ligands and receptors. While conventional views focus on the signals transmitted by the TCR and CD8 as a consequence of class I binding, we entertain the possibility that signals emanate from the class I molecule as a result of conformational changes induced by interactions with the TCR, CD8, or other ligands/receptors.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Mice

The B10.M/Sn, B10.S/SgMcdJ, BALB/cByJ, and B10.Q/SgJ mice, as well as the ß₂m knockout and human ß₂m (hß₂m) transgenic mice used in this study were obtained from the colony of Chella David (Mayo Clinic, Rochester, MN); the C.B10-H2^b (BALB.B) were obtained from Peter Wettstein (Mayo Clinic, Rochester, MN); the C57BL/6J and C57BL/6J-H-2^bm3/Eg mice were obtained from The Jackson Laboratories (Bar Harbor, ME); the K^bm3/D^d transgenic mice as well as the K^b/L^d transgenic mice were produced in this laboratory in collaboration with the David Laboratory for unrelated studies; the TAP knockout mice (129/OLA TAP1) were obtained from Dr. Anton Berns (The Netherlands Cancer Institute, Amsterdam, Netherlands). The mice were maintained in the animal facility at the Mayo Clinic.

Cell lines

The R8 cells and its variants, which were a gift from Dr. Stanley Nathanson (Albert Einstein College of Medicine, Bronx, NY), have been described previously (8). The cell lines, which harbor the chimeric class I molecules, were generated by Ken Arakawa in this laboratory or described previously (9). Briefly, the mouse fibroblast L cells were transfected by CaPO₄ precipitation of the construct, along with a thymidine kinase gene, onto the cells. The cells were cultured in RPMI 1640 complete medium, and transfectants were selected for viability with hypoxanthine/aminopterin/thymidine.

Abs and flow cytometry

The origin of the mAbs AF6-88.5, B8-24-3, K10.56, 28-13-3, and 64-3-7 have been listed previously (7, 10) and were used at binding-site-saturating concentrations. Detection of Abs was done using an FITC-conjugated goat anti-mouse IgG or IgM (Biosource International, Camarillo, CA). Flow cytometry was performed on a FACScan (Becton Dickinson, Mountain View, CA), and mean channel fluorescence values were obtained and converted to a linear scale.

Binding calculations

AF6-88.5 reactivity of variant and chimeric class I molecules was first determined relative to an unaffected epitope, as indicated in the tables and figures, and that proportion was compared with the proportion found on the wild-type K^b molecule expressed in comparable cell types (i.e., freshly isolated spleen cells, transfected L cells, or the R8 lymphoma line). The values reported is the ratio of the percent of AF6-88.5 binding to the variant molecule relative to the percent of AF6-88.5 binding to the wild-type molecule. Each binding experiment was repeated at least three times, and all data reported were reproducible. Representative fluorescence values are shown in Table II.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

AF6-88.5 is a mAb with high specificity for the class I allele K^b (7). The Ab was generated by immunizing a BALB/c mouse with splenocytes from a C57BL/6 mouse. During tests to confirm the reactivity of the Ab, we found that a mouse L cell line transfected with a chimeric class I molecule composed of the 1 and 2 domains of K^b, and the 3, transmembrane, and cytoplasmic domains of L^d failed to bind AF6-88.5 in a FACS assay. Reactivity against K^b was confirmed by showing that L cells transfected with genomic clones of K^b were positive, while transfectants of L^d were negative (Fig. 1 and Table I). Furthermore, splenocytes from a B6 mouse reacted positively with the Ab, while splenocytes from a B10.M transgenic mouse expressing the chimeric K^b/L^d molecule did not (data not shown).

View larger version (28K): [in this window] [in a new window]   FIGURE 1. Representative histogram showing AF6-88.5 staining intensity of L cells expressing Kb or a chimera with the 1 and 2 domains of Kb and the 3 domain of Ld. The solid curve represents L cells transfected with a gene for the chimeric molecule and the overlays represents a non-Ab control or L cells transfected with a genomic fragment of Kb as indicated.

View larger version (94K): [in this window] [in a new window]   FIGURE 3. Three-dimensional structure of Kb complexed with ß2m is shown with the peptide backbone represented as a tube within the transparent van der Waals radii. Amino acid residues highlighted on the 3 domain represent the differences between Kb and Ld in this domain. Additionally, the position of residues 162 and 174, which reside on a region of 2 that has been shown to affect the AF6-88.5 epitope, are also indicated. Each domain is shaded a different shade of gray to allow for easy visual distinction.

View larger version (20K): [in this window] [in a new window]   FIGURE 2. Histogram profiles of L cells transfected with a chimera that has the 1 domain derived from Ld and everything else from Kb. The temperature shift shows thermal stabilization of the chimeric molecule detected with the specific Abs 64-3-7 (Ld1) and K10.56 (Kb2) and lack of specific binding by B8-24-3 and AF6-88.5 as indicated. The same profile for B8-24-3 is shown in each panel as a negative reference marker, and multiple panels are shown for clarity.

To determine the effects of previously described mutations that influence the structure of the peptide-binding site formed by the 1 and 2 domains of the K^b molecule, the ability of the AF6-88.5 Ab to bind splenocytes from the K^bm3, K^bm5, and K^bm8 mutant mice or L cells expressing transfected K^bm1 and K^bm10 genes were tested. Each of these mutant K^b molecules displays altered peptide-binding properties and TCR recognition. For most cases, that changes can be visualized with 1/2-specific mAbs (9, 13, and our unpublished observations). None of the mutations had any significant influence on the expression of the AF6-88.5-defined epitope (Table III). Consistent with our previous finding that the 3 region influences AF6-88.5-recognition, cells transfected with a chimeric molecule that is comprised of the 1 and 2 domains of K^bm3 and the 3, transmembrane, and cytoplasmic tail of D^d were negative, as were splenocytes from a mouse expressing the chimeric class I molecule from a transgene (Table III).

To assess the role of peptides within the binding site, spleen cells from mice genetically deficient for the TAP complex were analyzed. Cells from these mice have reduced surface expression of K^b, as the class I molecules are not assembled with peptide within the endoplasmic reticulum (14). Reduced levels of K^b were detected relative to wild-type cells, and the proportion of AF6-88.5 reactivity relative to K10.56 reactivity was roughly half that proportion on wild-type cells (Table IV). Therefore, we concluded that the absence of high-affinity peptide had some effect on the AF6-88.5-defined epitope. A study has been previously reported that found no influence of 40 different OVA-derived peptide analogues on AF6-88.5 binding (11). This indicates that, while the presence of high-affinity peptide has an effect on the AF6-88.5 epitope, the nature of peptides that are bound did not.

We wished to assess whether ß₂m participated in the formation of the AF6-88.5 epitope. We determined that K^b complexed to the "b" allele of ß₂m had no effect on the AF6-88.5 epitope by analyzing BALB.B splenocytes (Table IV). To determine whether the AF6-88.5-defined epitope could be detected on ß₂m deficient cells, spleen cells from a ß₂m-deficient mouse expressing K^b were examined. These cells were found to be negative, which was not surprising as these cells do not express any known class I epitopes on their cell surface in appreciable quantities (15). Next, AF6-88.5 recognition was assessed on cells after restoring class I expression with a human ß₂m transgene. Despite the presence of K^b on the surface of spleen cells from this mouse as detected by several mAbs, the AF6-88.5-defined epitope was not detected (Table IV). From this, we conclude that mAb AF6-88.5 recognizes an epitope that is dependent on all four extracellular domains of the K^b molecule.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

 
In this report, we have characterized sequences that determine the structure of the binding site of the mAb, AF6-88.5, on the mouse class I molecule, K^b. The impetus for this came from our inability to use AF6-88.5 to visualize K^b on fixed tissue and by the subsequent discovery that the Ab would not bind a K^b chimera containing the 3 domain of L^d. We found it surprising that the nine amino acid differences in the 3 domain, most of which are far away from the Ag-binding domain in the three-dimensional structure (Fig. 3), would influence the binding of an Ab reported to recognize sequences in the 2 region. Furthermore, site-directed mutagenesis showed that the eight distal-most residues from the peptide-binding domain in 3 that differ between K^b and L^d were sufficient to disrupt AF6-88.5 binding. That K^q, as well as all the other chimeras between K^b and L^d, all failed to bind the Ab suggested to us that there must be some kind of interaction among the 1, 2, and 3 domains that determine the structure of the epitope. The epitope forms only when K^b sequences are present in each of the domains and is disrupted by amino acid substitutions in each of the external domains of the protein.

The R8 cell line mutants, as well as the "bm" mutant series, were originally isolated for changes in mAb and TCR-binding properties (8, 16). By definition, this set of mutants has structural divergence from K^b mapping in the 1 and 2 regions. With the exception of G162P and N174K, none had an impact on the AF6-88.5-defined determinant, indicating that the conformational changes they produce are not overlapping with the AF6-88.5-epitope. It should be pointed out that the substitution at position 162 results in a proline at a position that links two helices, and the substitution at 174 results in two adjacent lysine residues. The former might not be predicted to have an effect although it is destabilizing to AF6-88.5, and the latter might be predicted to have a disruptive effect on the structure although it results in stabilization of the structurally sensitive epitope.

Others have found that ß₂m has a role in stabilizing the heavy chain, and there have been other mAb described that are dependent on ß₂m (17). Indeed, some have found that xenogeneic ß₂m has higher affinity for mouse heavy chains and provided for greater stability of the complex than mouse ß₂m (18). Recent studies indicate that ß₂m plays an essential role in the endoplasmic reticulum as it interacts with the heavy chain and facilitates its proper folding (19). It is also worth noting that numerous murine class I molecules, when complexed with human or bovine ß₂m, acquire some affinity for the monomorphic anti-HLA class I mAb, W6/32. This binding appears to associate with the murine 2 domain (20, 21, 22), which would demonstrate an influence of ß₂m on murine heavy chain structure. To assess what role ß₂m might have in formation of the epitope, we used a ß₂m-deficient mouse as well as a mouse ß₂m-deficient cell line reconstituted with hß₂m. We found that the AF6-88.5-defined epitope is dependent on both K^b and mouse ß₂m (Table IV).

Thus, all of the major elements of the class I complex influence the AF6-88.5-defined determinant. A report from Chen et al. cites the use of two antigenic OVA peptides and their reciprocally substituted analogues bound to K^b and found that the AF6-88.5 epitope formed regardless of which peptide was used. We were able to recapitulate this finding using RMA-S cells and the dominant OVA peptide (data not shown).

Examination of the three-dimensional structure of K^b reveals a point where all three of the domains of the heavy chain as well as ß₂m come together (Fig. 3). We have not been able to define the exact determinant for AF6-88.5 and cannot formally exclude that it is represented by this area. However, we find it unlikely that it represents the center of the Ab-binding site given the apparent inaccessibility of this point. Even if this were the area where this Ab was binding, the positions of the residues that influence binding still force us to conclude that structural perturbations can radiate throughout all the domains of the molecule.

The majority of the efforts made to assess changes in class I conformation have focused on using different peptides bound in the binding cleft or mutants of the heavy chain that directly alter the physical properties of the peptide-binding site (23, 24, 25, 26). These studies fit current paradigms well, as all the structural data reported over the past decade has shown that this is the region where immune recognition takes place. It has therefore been of the most potential value to study the peptide binding region of class I in an attempt to understand the molecular details surrounding class I-TCR interactions.

Here we have shown that the mAb, AF6-88.5, recognizes an epitope on the mouse class I molecule, K^b, which is sensitive to modifications of residues in all parts of the heavy chain as well as to the nature of the ß₂m, but is insensitive to the nature of bound peptide. This implies the existence of an additional conformationally sensitive site(s) on class I molecules. The question of whether such changes have biological relevance remains to be answered.

There is increasing evidence that molecular interactions involving regions of the class I molecule outside of the peptide-presenting domain not only play important functions during T cell/APC interactions, but also have a role in the function of class I molecules on intracellular signaling pathways (27, 28, 29). An example of a large change in the positions of 3 and ß₂m relative to 12 in the receptor-bound structure was observed and comes from the recent description of the high-resolution crystal structure of the entire complex of K^b bound by TCR (30). Another recent example of structural plasticity comes from the analysis of HLA-A2 complexed with CD8 (5). The observation of structural shifts in the 3 domain that accompany binding of CD8 to the class I molecule suggests a potential role for these structural changes in immune recognition. The finding that CD8 enhances the affinity of the class I TCR interaction (6) is supportive of this view. Another demonstration of large-scale structural changes that occur as a consequence of receptor-ligand interaction comes from Reich et al., where they described the oligomerization of TCR/peptide-MHC complexes while such oligomerization did not occur with either molecule by themselves or with a nonantigenic peptide (31).

While the static structures described above point to a functional role for regions of the class I molecule distinct from the TCR interaction domain, an example showing significance for such regions on molecules in a live membrane comes form the observation that Abs specific for the 3 domain have been shown to inhibit signals transduced through the TCR (32). That the cytoplasmic domain of the class I molecule is not required for this function implies that intermolecular interactions occurring between other membrane molecules and the extracellular domains of class I may be important (33). Whether activation of these negative signals by Abs is the result of conformational changes or cross-linking is not known.

There are now a large number of crystal structures of class I molecules that have been determined, and 3 and ß₂m are the areas which show the greatest deviation from structure to structure. While this fact makes it difficult to conclude that such structural alterations are a consequence of receptor or ligand binding, it also indicates that these areas are likely to be capable of such fluctuations at the cell surface and that makes them attractive candidates for mediating other intermolecular interactions. Our finding that the AF6-88.5 mAb recognizes a conformationally sensitive epitope outside of the peptide-binding site of class I not only indicates that class I is capable of considerable structural fluidity, but that AF6 could serve as a valuable tool in exploring situations that may bring about a conformational shift in K^b.

	Acknowledgments

 
We thank Michael Hansen and Kathleen Allen for their excellent technical assistance.

	Footnotes

 
¹ Address correspondence and reprint requests to Dr. Larry R. Pease, Mayo Clinic/Foundation, 200 First Street SW, Rochester, MN 55905.

² Abbreviations used in this paper: ß₂m, mouse ß₂-microglobulin; hß₂m, human ß₂-microglobulin.

Received for publication November 12, 1997. Accepted for publication August 28, 1998.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Bjorkman, P. J., M. A. Saper, B. Samraovi, W. S. Bennett, J. L. Strominger, D. C. Wiley. 1987. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 329:512.[Medline]
2. Zhang, W., A. C. Young, M. Imarai, S. G. Nathansen, J. C. Sacchettini. 1992. Crystal structure of the major histocompatibility complex class I H-2 K^b molecule containing a single viral peptide: implications for peptide binding and T cell receptor recognition. Proc. Natl. Acad. Sci. USA 89:8403.[Abstract/Free Full Text]
3. Garcia, K. C., M. Degano, R. L. Stanfield, A. Brunmark, M. R. Jackson, P. A. Peterson, L. Teyton, I. A. Wilson. 1996. An ß T cell receptor structure at 2.5 Å and its orientation in the TCR-MHC complex. Science 274:209.[Abstract/Free Full Text]
4. Garboczi, D. N., P. Ghosh, U. Utz, Q. R. Fan, W. E. Biddison, D. C. Wiley. 1996. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 384:134.[Medline]
5. Gao, G. F., J. Tormo, U. C. Gerth, J. R. Wyer, A. J. McMichael, D. I. Stuart, J. I. Bell, E. Y. Jones, B. K. Jakobsen. 1997. Crystal structure of the complex between human CD8 alpha and HLA-A2. Nature 38:630.
6. Garcia, K. C., C. A. Scott, A. Brunmark, F. R. Carbone, P. A. Peterson, I. A. Wilson, L. Teyton. 1996. CD8 enhances formation of stable T-cell receptor/MHC class I molecule complexes. Nature 384:577.[Medline]
7. Loken, M. R., A. M. Stall. 1982. Flow cytometry as an analytical and preparative tool in immunology. J. Immunol. Meth. 50:R85.[Medline]
8. Geier, S. S., R. A. Zeff, D. M. McGovern, T. V. Rajan, S. G. Nathenson. 1986. An approach to the study of structure-function relationships of MHC class I molecules: isolation and serologic characterization of H-2 K^b somatic cell variants. J. Immunol. 137:1239.[Abstract]
9. Pullen, J. K., H. D. Hunt, R. M. Horton, L. R. Pease. 1989. The functional significance of two amino polymorphisms in the antigen-presenting domain of class I MHC molecules: molecular dissection of K^bm3. J. Immunol. 143:1674.[Abstract]
10. Hunt, H. D., T. I. Munitz, L. R. Pease.. 1992. Alloreactive cytotoxic T lymphocytes recognize epitopes determined by both the helices and ß sheets of the class I peptide binding site. J. Immunol. 175:821.
11. Chen, W., J. Fecondo, J. McCluskey. 1994. The structural influence of individual residues located within peptide antigen depends upon their sequence context. Mol. Immunol. 31:1069.[Medline]
12. Pullen, J. K., R. M. Horton, Z. Cai, L. R. Pease. 1992. Structural diversity of the classical H-2 genes: K, D, and L. J. Immunol. 148:953.[Abstract]
13. Sherman, L., C. D. Randolph. 1981. Monoclonal anti-H-2 K^b antibodies detect serological differences between H-2 K^b mutants. Immunogenetics 12:183.[Medline]
14. Van Kaer, L., P. G. Ashton-Rickardt, H. L. Ploegh, S. Tonegawa. 1992. Tap 1 mutant mice are deficient in antigen presentation, surface class I molecules, and CD4-CD8⁺ T cells. Cell 71:1205.[Medline]
15. Zijlstra, M., M. Bix, N. E. Simister, J. M. Loring, D. H. Raulet, R. Joenisch. 1990. [Beta]-2-microglobulin deficient mice lack CD4^-8⁺ cytolytic T cells. Nature 344:742.[Medline]
16. Nathansen, S. G. J., G. M. Pfaffenbach Beliebter, R. A. Zeff. 1986. Murine major histocompatibility complex class I mutants: molecular analysis and structure function implications. Annu. Rev. Immunol. 4:471.[Medline]
17. Smith, J. D., N. B. Myers, J. Gorka, T. H. Hansen. 1993. Model for the in vivo assembly of nascent L^d class I molecules and for the expression of unfolded L^d molecules at the cell surface. J. Exp. Med. 178:2035.[Abstract/Free Full Text]
18. Rocca, A., A. Opolski, A. Samaan, B. Frangoulis, L. Degos, M. Pla. 1992. Localization of the conformational alteration of MHC molecules induced by the association of mouse class I heavy chain with a xenogeneic ß₂-microglobulin. Mol. Immunol. 29:481.[Medline]
19. Solheim, J. C., N. A. Johnson, B. M. Carreno, W-R. Lie, T. H. Hansen. 1995. ß₂-microglobulin with an endoplasmic reticulum retention signal increases the surface expression of folded class I major histocompatibility complex molecules. Eur. J. Immunol. 25:3011.[Medline]
20. Barnstable, C. J., W. F. Bodmer, G. Brown, G. Galfre, C. Milstein, A. F. Williams, A. Ziegler. 1978. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens: new tools for genetic analysis. Cell 14:9.[Medline]
21. Jefferies, W. A., G. G. MacPherson. 1987. Expression of the W6/32 HLA epitope by cells of rat, mouse, human, and other species: critical dependence on the interaction of specific MHC heavy chains with human or bovine ß₂-microglobulin. Eur. J. Immunol. 17:1257.[Medline]
22. Kahn-Perles, B., C. Boyer, B. Arnold, A. Sanderson, P. Ferrier, F. Lemonnier. 1987. Acquisition of HLA class I W6/32 defined antigenic determinant by heavy chains from different species following association with bovine ß₂-microglobulin. J. Immunol. 138:2190.[Abstract]
23. Pease, L. R., R. M. Horton, J. K. Pullen, H. D. Hunt, T. J. Yun, E. M. Rohren, J. L. Prescott, S. M. Jobe, K. S. Allen. 1993. Amino acid changes in the peptide binding site have structural consequences at the surface of class I glycoproteins. J. Immunol. 150:3375.[Abstract]
24. Rohren, E. M., D. J. McCormick, L. R. Pease. 1994. Peptide-induced conformational changes in class I molecules: direct detection by flow cytometry. J. Immunol. 152:5337.[Abstract]
25. Catipovid, B., J. Dal Porto, M. Mage, T. E. Johansen, J. P. Schneck. 1992. Major histocompatibility complex conformational epitopes are peptide specific. J. Exp. Med. 176:1611.[Abstract/Free Full Text]
26. Bluestone, J. A., S. Jameson, S. Miller, II. R. Dick. 1992. Peptide-induced conformational changes in class I heavy chains alter major histocompatibility complex recognition. J. Exp. Med. 176:1757.[Abstract/Free Full Text]
27. Skov, S., N. Odum, M. H. Claesson. 1995. MHC class I signaling in T cells leads to tyrosine kinase activity and PLC- 1 phosphorylation. J. Immunol. 154:1167.[Abstract]
28. Wagner, N., P. Engel, M. Vega, T. F. Tedder. 1994. Ligation of MHC class I and class II molecules can lead to heterologous desensitization of signal transduction pathways that regulate homotypic adhesion in human lymphocytes. J. Immunol. 152:5375.[Abstract]
29. Dasgupta, J. D., C. B. Granja, E. J. Yunis, V. Relias. 1994. MHC class I antigens regulate CD3-induced tyrosine phosphorylation of proteins in T cells. Int. Immunol. 6:481.[Abstract/Free Full Text]
30. Garcia, K. C., M. Degano, L. R. Pease, M. Huang, P. A. Peterson, L. Teyton, I. A. Wilson. 1998. Structural basis of plasticity in T cell receptor recognition of a self peptide-MHC antigen. Science 279:1166.[Abstract/Free Full Text]
31. Reich, Z., J. J. Boniface, D. S. Lyons, N. Borochov, E. J. Wachtel, M. M. Davis.. 1997. Ligand-specific oligomerization of T-cell receptor molecules. Nature 387:617.[Medline]
32. Smith, D. M., J. A. Bluestone, D. R. Jeyarajah, M. H. Newberg, V. H. Engelhard, J. R. Thistlethwaite, E. S. Woodle. 1994. Inhibition of T cell activation by a monoclonal antibody reactive against the 3 domain of human MHC class I molecules. J. Immunol. 153:1054.[Abstract]
33. Gur, H., F. el-Zaatari, T. D. Geppert, M. C. Wacholtz, J. D. Taurog, P. E. Lipsky. 1990. Analysis of T cell signaling by class I MHC molecules: the cytoplasmic domain is not required for signal transduction. J. Exp. Med. 172:1267.[Abstract/Free Full Text]

This article has been cited by other articles:

				C. F. Towne, I. A. York, J. Neijssen, M. L. Karow, A. J. Murphy, D. M. Valenzuela, G. D. Yancopoulos, J. J. Neefjes, and K. L. Rock Puromycin-Sensitive Aminopeptidase Limits MHC Class I Presentation in Dendritic Cells but Does Not Affect CD8 T Cell Responses during Viral Infections J. Immunol., February 1, 2008; 180(3): 1704 - 1712. [Abstract] [Full Text] [PDF]

				L. A. Benoit and R. Tan Xenogeneic beta2-Microglobulin Substitution Alters NK Cell Function J. Immunol., August 1, 2007; 179(3): 1466 - 1474. [Abstract] [Full Text] [PDF]

				C. F. Towne, I. A. York, L. B. Watkin, J. S. Lazo, and K. L. Rock Analysis of the Role of Bleomycin Hydrolase in Antigen Presentation and the Generation of CD8 T Cell Responses J. Immunol., June 1, 2007; 178(11): 6923 - 6930. [Abstract] [Full Text] [PDF]

				C. F. Towne, I. A. York, J. Neijssen, M. L. Karow, A. J. Murphy, D. M. Valenzuela, G. D. Yancopoulos, J. J. Neefjes, and K. L. Rock Leucine Aminopeptidase Is Not Essential for Trimming Peptides in the Cytosol or Generating Epitopes for MHC Class I Antigen Presentation J. Immunol., November 15, 2005; 175(10): 6605 - 6614. [Abstract] [Full Text] [PDF]

				L. A. Benoit, J. Shannon, J. W. Chamberlain, and R. G. Miller Influence of Xenogeneic {beta}2-Microglobulin on Functional Recognition of H-2Kb by the NK Cell Inhibitory Receptor Ly49C J. Immunol., September 15, 2005; 175(6): 3542 - 3553. [Abstract] [Full Text] [PDF]

				J. Michaelsson, A. Achour, A. Rolle, and K. Karre MHC Class I Recognition by NK Receptors in the Ly49 Family Is Strongly Influenced by the {{beta}}2-Microglobulin Subunit J. Immunol., June 15, 2001; 166(12): 7327 - 7334. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kuhns, S. T. Articles by Pease, L. R. Search for Related Content PubMed PubMed Citation Articles by Kuhns, S. T. Articles by Pease, L. R.